Inclusion Criteria – REPEAT INJECTION continued
Exclusion Criteria
Cautions/Need for Further Advice
Approval Date:
16.2.2012
Medical and family history has been taken and there is no reason for exclusion. Treatment of clients aged 16 years or younger must meet Fraser guidelines. **NOTE Repeat doses given after 89 days (12 weeks and 5 days) is outside the product license. Refer to additional information for further advice. Informed consent has NOT been given in accordance with current Locala Community Partnership (LCP) guidelines for the supply of the medicine Previous adverse reactions to Depo-Provera or a constituent or allergy to any progestogen Current or past history of breast cancer Known or suspected pregnancy Greater than 14 weeks since last injection and has had unprotected intercourse Age above 50 years or under 13 years. Fraser competence not confirmed. Unexplained vaginal bleeding (suspicious for serious underlying conditions) Diabetes with nephropathy, retinopathy or neuropathy Diabetes with other vascular disease Current or history of stroke Current and history of ischaemic heart disease Significant multiple risk factors for arterial cardiovascular disease e.g. older age, diabetes, smoking and hypertension Vascular disease (includes CHD presenting with angina; peripheral vascular disease presenting with intermittent claudication; hypertensive retinopathy and transient ischaemic attacks) Systemic lupus erythematosus (SLE) with positive (or unknown) antiphospholipid antibodies or with severe thrombocytopenia. Before menarche Active viral hepatitis History of liver tumour (benign or malignant) Severe cirrhosis Any medical condition of unknown significance or taking any medication that is of unknown significance to the nurse. Clients who have not be reviewed by a doctor or nurse prescriber within the last 2 years. The CSM has advised that in adolescents, Depo-Provera, should only be used when other methods of contraception are inappropriate. See ‘loss of bone mineral density’ in special considerations/additional information. Consistently elevated blood pressure readings – refer to GP. Established or significant risk of osteoporosis, if uncertain give and refer to doctor for next injection Serious weight gain, give life style advice and consider alternative method Patients with a history of endogenous depression should be carefully monitored. Some patients may complain of premenstrual-type depression while on Depo-Provera therapy.
PGD No 66 v2 - Depo Provera Injection Review Date: 31.3.2014 Page 2